For other endpoints, the differences between the treatment groups at week 24 were mostly not statistically significant and/or small, but with a numerical trend towards superiority of the add-on strategy.
← all excerpts
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY).
1
—
—